评价网 > 科教论文 > 医学毕业论文 > 药学论文 > 正文

抗肿瘤抗生素与癌症靶向治疗论文(3)

2013-07-27 01:07 ib and 17AAG in imatinibresistant CML cells overexpressing BCRABLInhibition of Pglycoprotein ［J］. Leukemia,2005,19(7):1198

　　［18］ Liu M, Howes A, Lesperance J, et al. Antitumor activity of rapamycin in a transgenic mouse model of ErbB2dependent human breast cancer ［J］. Cancer Res,2005,65(12):5325

　　［19］ Ross J S, Schenkein D P, Pietrusko R, et al. Targeted therapies for cancer 2004 ［J］. Am J Clin Pathol,2004,122(4):598

　　［20］ Chester K, Pedley B, Tolner B, et al. Engineering antibodies for clinical applications in cancer ［J］. Tumour Biol,2004,25(1～2):91

　　［21］ 甄永苏. 单克隆抗体物治疗肿瘤的研究现状与展望［J］. 中国科学院学报，2000，22(1)：9

　　［22］ Carter P. Improving the efficacy of antibodybased cancer therapies ［J］. Nat Rev Cancer,2001,1(2):118

　　［23］ Fenton C, Perry C M. Gemtuzumab ozogamicin: a review of its use in acute myeloid leukaemia ［J］. Drugs,2005,65(16):2405

　　［24］ Hamann P R, Hinman L M, Beyer C F, et al. A calicheamicin conjugate with a fully humanized antiMUC1 antibody shows potent antitumor effects in breast and ovarian tumor xenografts ［J］. Bioconjug Chem,2005,16(2):354

　　［25］ Hamann P R, Hinman L M, Beyer C F, et al. An antiMUC1 antibodycalicheamicin conjugate for treatment of solid tumors. Choice of linker and overcoming drug resistance ［J］. Bioconjug Chem,2005,16(2):346

　　［26］ 刘小云，甄永苏. 力达霉素构建的小型化单克隆抗体免疫偶联物的抗肿瘤作用［J］. 中国医学科学院学报，2001，23(6)：563

　　［27］ 王风强，尚伯杨，甄永苏. 以IV型胶原酶为靶点的小型化免疫偶联物的抗肿瘤作用［J］. 中国科学(C辑)，2003，33(4)：329

　　［28］ Li L, Huang Y H, Miao Q F,et al. FvLDPAE, an engineerd and enediyneenergized fusion protein, shows highly potent antitumor efficacy and antiangiogenic activity ［J］. Proc Am Assoc Cancer Res,2004,45:2994

　　［29］ Miao Q F, Shang B, Zhen Y S. An engineered and energized fusion protein containing antibody VH domain and lidamycin shows potent antitumor efficacy ［J］. Proc Am Assoc Cancer Res,2005,46:559